47 recruiting, 30 completed, 15 active not recruiting, 14 terminated. 53 Phase 2, 27 Phase 1, 25 Not applicable, 9 Phase 3, 1 Early Phase 1.
Follow Esophageal Adenocarcinoma: new trials by email Literature Review of Esophageal Adenocarcinoma trials Research Report on Esophageal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 600 | 2027-02-01 | 2026-09-14 |
| Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial Cancer Screening, Computer-Assisted Intervention, Endoscopic Procedure - Barrett Esophagus, Esophageal Adenocarcinoma | Not applicable | Not yet recruiting | Mayo Clinic | 1010 | 2026-12-01 | 2026-06-24 |
| A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine - Esophageal Cancer, Advanced Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2026-09-04 | 2026-09-14 |
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2026-09-01 | 2026-06-05 |
| Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Esophageal Adenocarcinoma | Phase 2 | Recruiting | Duke University | 60 | 2026-09-01 | 2026-09-29 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Denikitug, Nivolumab, Ramucirumab - HER2-negative, Gastroesophageal Junction | Phase 2 | Recruiting | Gilead Sciences | 120 | 2026-08-07 | 2026-09-21 |
| Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus Biopsy Procedure, Biospecimen Collection, Endoscopic Procedure - Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2026-06-23 | 2026-09-14 |
| Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma Standard of care chemotherapy, LNSC - Esophageal Adenocarcinoma, Esophageal Cancer | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 40 | 2026-06-10 | 2026-08-18 |
| Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test - Foregut Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Recruiting | Yale University | 54 | 2026-06-02 | 2026-09-08 |
| ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu Tremelimumab, Durvalumab - Solid Tumor, Adult, Malignant Solid Tumor | Early Phase 1 | Recruiting | University of California, Irvine | 34 | 2026-05-25 | 2026-07-07 |
| Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer PF-08634404, Chemotherapy, Nivolumab - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer | Phase 2 / Phase 3 | Recruiting | Pfizer | 840 | 2026-05-14 | 2026-10-13 |
| A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers DISP-10 - Colorectal Cancer, Gastric Adenocarcinoma | Phase 1 | Recruiting | Dispatch Biotherapeutics | 66 | 2026-04-13 | 2026-10-05 |
| Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) Givastomig, Nivolumab, 5Fluorouracil - Solid Tumor, Advanced Cancer | Phase 2 | Recruiting | I-Mab Biopharma US Limited | 180 | 2026-02-11 | 2026-05-14 |
| A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma Tislelizumab, FLOT Chemotherapy - Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 18 | 2025-12-12 | 2025-12-19 |
| First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors PLX-61639 - Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Plexium, Inc. | 155 | 2025-12-01 | 2026-06-12 |
| Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma Non-Interventional Study - Barrett Esophagus, Esophageal Adenocarcinoma | Enrolling by invitation | Mayo Clinic | 450 | 2025-11-17 | 2026-09-29 | |
| Patient Preference for Subcutaneous vs. Intravenous Immune Therapy nivolumab, pembrolizumab - Renal Cell Carcinoma, Non Small Cell Lung Cancer | Phase 2 | Recruiting | Diwakar Davar | 880 | 2025-11-04 | 2026-04-16 |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NRM-823 - HNSCC, ESCC | Phase 1 | Recruiting | Normunity AccelCo, Inc. | 150 | 2025-10-30 | 2026-08-18 |
| Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice Nivolumab - Esophageal Adenocarcinoma, Gastro-esophageal Junction Adenocarcinoma | Active not recruiting | Bristol-Myers Squibb | 726 | 2025-10-09 | 2026-06-23 | |
| Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy Low Dose Radiation Therapy - Esophageal Adenocarcinoma, Radiotherapy | Phase 2 | Not yet recruiting | Fudan University | 32 | 2025-09-01 | 2025-09-10 |
Showing 20 of 126. Sign in to see all of them.
Adenocarcinoma Of Esophagus (126) · Barrett Esophagus (37) · Esophageal Neoplasms (24) · Stomach Neoplasms (23) · Esophageal Squamous Cell Carcinoma (17) · Gastroesophageal Reflux (10) · Carcinoma, Non-Small-Cell Lung (9) · Neoplasm Metastasis (8) · Squamous Cell Carcinoma of Head and Neck (8) · Cholangiocarcinoma (7) · Colorectal Neoplasms (7) · Carcinoma, Hepatocellular (5) · Pancreatic Neoplasms (5) · Carcinoma, Renal Cell (4) · Carcinoma, Transitional Cell (4)
Neoplasms (94) · Digestive System Diseases (88) · Gastrointestinal Diseases (85) · Esophageal Diseases (67) · Neoplasms by Site (60) · Digestive System Neoplasms (56) · Gastrointestinal Neoplasms (52) · Head and Neck Neoplasms (37) · Precancerous Conditions (37) · Neoplasms by Histologic Type (33) · Carcinoma (30) · Neoplasms, Glandular and Epithelial (30) · Stomach Diseases (23) · Carcinoma, Squamous Cell (20) · Pathological Conditions, Signs and Symptoms (20)
Oxaliplatin (19) · Fluorouracil (16) · pembrolizumab (15) · Nivolumab (14) · Leucovorin (13) · Capecitabine (11) · Carboplatin (10) · Paclitaxel (9) · Trastuzumab (8) · durvalumab (6) · Cisplatin (5) · Endoscopy, Digestive System (5) · Radiation (5) · tremelimumab (5) · Docetaxel (4)
Mayo Clinic (6) · National Cancer Institute (NCI) (6) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (5) · Columbia University (4) · Memorial Sloan Kettering Cancer Center (4) · City of Hope Medical Center (3) · Lucid Diagnostics, Inc. (3) · Seagen, a wholly owned subsidiary of Pfizer (3) · University of Colorado, Denver (3) · Bristol-Myers Squibb (2) · Case Comprehensive Cancer Center (2) · I-Mab Biopharma US Limited (2) · Massachusetts General Hospital (2) · Midwest Biomedical Research (2) · OHSU Knight Cancer Institute (2)
United States (89) · Netherlands (15) · Germany (13) · Spain (12) · United Kingdom (12) · China (11) · France (11) · Japan (11) · Canada (10) · South Korea (8) · Taiwan (7) · Australia (6) · Belgium (6) · Italy (6) · Israel (3)
Ajay Bansal, MD (2) · Geoffrey Ku, MD (2) · Hanneke WM van Laarhoven, MD, PhD (2) · Julian A. Abrams, MD, MS (2) · Nicholas J Shaheen, MD, MPH (2) · Prasad G. Iyer, MD (2) · Sachin Wani, MD (2) · Thierry Alcindor, MD, MSc (2) · Victoria Lee, MD (2) · Ahmed Bolkhir, MD (1) · Ajay Goel, PhD (1) · Allison Nitsch, MD (1)
PMID 19559419, PMID 21407181, PMID 28760152, PMID 29933761, PMID 29948566, PMID 30342494, PMID 32058557, PMID 32346484, PMID 33512805, PMID 33986123, PMID 34102137, PMID 34565343, PMID 35038433, PMID 35048809, PMID 35426404, PMID 35426405, PMID 35945625, PMID 36000541, PMID 36121651, PMID 36137639, PMID 36200668, PMID 36919706, PMID 37270871, PMID 37423873, PMID 37619980, PMID 37713657, PMID 37860278, PMID 38378868, PMID 38382001, PMID 38513982, PMID 38619114, PMID 39448207, PMID 39562048, PMID 39588974, PMID 40239627, PMID 40341124, PMID 40571483, PMID 40632415, PMID 40721981, PMID 40759445, PMID 41108088, PMID 41324998, PMID 41724817, PMID 42202319, PMID 42814447
2023 (3), 2025 (3), R01CA241164 (3), 2018 (2), P30CA046592 (2), UG1CA242632 (2), 2016 (1), I01CX002349 (1), N01CN00034 (1), P30CA014599 (1), P30CA016672 (1), P30CA033572 (1), P30CA036727 (1), P30CA069533 (1), R01CA255298 (1)